Anti-oxidant ebselen delays microvascular thrombus formation in the rat cremaster muscle by inhibiting platelet P-selectin expression

Nicole Lindenblatt; Wolfgang Schareck; Lorenz Belusa; Ruth Maria Nickels; Michael Dieter Menger; Brigitte Vollmar

doi:10.1160/TH02-09-0093

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2003; 90(05): 882-892
DOI: 10.1160/TH02-09-0093

Platelets and Blood Cells

Schattauer GmbH

Anti-oxidant ebselen delays microvascular thrombus formation in the rat cremaster muscle by inhibiting platelet P-selectin expression

Authors

Nicole Lindenblatt

¹Department of Experimental Surgery, University of Rostock, Germany

²Department of General Surgery, University of Rostock, Germany
Wolfgang Schareck

²Department of General Surgery, University of Rostock, Germany
Lorenz Belusa

²Department of General Surgery, University of Rostock, Germany
Ruth Maria Nickels

³Department of Clinical-Experimental Surgery, University of Saarland, Homburg/Saar, Germany
Michael Dieter Menger

³Department of Clinical-Experimental Surgery, University of Saarland, Homburg/Saar, Germany
Brigitte Vollmar

¹Department of Experimental Surgery, University of Rostock, Germany

Abstract

Summary

Ebselen, a seleno-organic compound showing glutathione peroxidase-like activity, has potent anti-inflammatory and anti-oxidant effects. Since selenium deficiency is thought to be associated with an increased incidence of vascular thrombosis, we studied the effect of ebselen on blood cell aggregate formation and vessel occlusion in vivo. In individual microvessels of rat cremaster muscle preparations, photochemically induced thrombus formation was analyzed in detail using intravital fluorescence microscopy. In ebselen-pretreated animals (30mg/kg ip), venular thrombus formation was significantly delayed (50% vessel occlusion: 535±34s; initial stasis: 872±82s; complete occlusion: 908±87s) as compared to vehicle-treated controls (416±42; 612±49; 647±51). Moreover, ebselen significantly prolonged the kinetics of arteriolar thrombus formation and even completely prevented blood cell aggregate and thrombus formation in 88.9% of all arterioles studied (p<0.05 vs controls:37.5%). Anti-thrombotic properties of ebselen could also be observed in a model of ferric chloride-induced microvascular thrombosis, with a low dose (5mg/kg ip) being as effective as a high dose pretreatment (30mg/kg ip). As assessed by flow cytometry of platelet P-selectin immunfluorescence, whole blood isolated from ebselen-treated animals revealed a significantly lower fraction of P-selectin expressing platelets when compared with that of DMSO-treated controls. In addition, oxidant stress-induced upregulation of P-selectin on isolated platelets was found dose-dependently inhibited by increasing concentrations of ebselen (10-100µM). Moreover, ebselen dose-dependently inhibited H₂O₂-induced platelet-leukocyte aggregate formation in whole blood in vitro, suggesting that the anti-thrombotic effect of ebselen is achieved by attenuation of P-selectin dependent platelet-leukocyte aggregation. Thus, ebselen represents preventive and therapeutic value for disorders with increased risk for oxidant stress-associated thrombotic events.

Keywords

Thrombosis - platelet - leukocyte - fluorescence microscopy - flow cytometry - oxidant stress

Full Text

References

References
1 Salonen JT, Alfthan G, Huttunen JK. et al Association between cardiovascular death and myocardial infarction and serum selenium in a matched-paired longitudinal study. Lancet 1982; 2: 175-9.
2 Moore JA, Noiva R, Wells IC. Selenium concentrations in plasma of patients with arteriographicallly defined coronary atherosclerosis. Clin Chem 1984; 30: 1171-3.
3 Jackson ML. Selenium: geochemical distribution and associations with human heart and cancer death rates and longevity in China and the United States. Biol Trace Elem Res 1988; 15: 13-21.
4 Wang YX, Bocker K, Reuter H. et al Selenium and myocardial infarction: glutathi-one peroxidase in platelets. Klin Wochenschr 1981; 59: 817-818.
5 Guidi GC, Schiavon R, Sheiban I. et al Platelet glutathione peroxidase activity is impaired in patients with coronary heart disease. Scand J Clin Lab Invest 1986; 46: 549-51.
6 Perona G, Guidi GC, Piga A. et al In vivo and in vitro variations of human erythrocyte glutathione peroxidase activity as result of cells aging, selenium availability and peroxide activation. Br J Haematol 1978; 39: 399-408.
7 Levander OA, Alfthan G, Arvilommi H. et al Bioavailability of selenium to Finnish men as assessed by platelet glutathione peroxidase activity and other blood parameters. J Clin Nutr 1983; 37: 887-897.
8 Kasperek K, Iyengar GV, Kiem J. et al Elemental composition of platelets. Part III. Determination of Ag, Au, Cd, Co, Cr, Cs, Mo, Rb, Sb, and Se in normal human platelets by neutron activation analysis. Clin Chem 1979; 25: 711-5.
9 Guidi GC, Schiavon R, Biasioli A. et al The enzyme glutathione peroxidase in arachidonic acid metabolism of human platelets. J Lab Clin Med 1984; 104: 574-582.
10 Perona G, Schiavon R, Guidi GC. et al Selenium dependent glutathione peroxidase: a physiogical regulatory system for platelet function. Thromb Haemost 1990; 64: 312-8.
11 Ricetti MM, Guidi GC, Tecchio C. et al Effects of sodium selenite on in vitro interactions between platelets and endothelial cells. Int J Clin Lab Res 1999; 29: 80-4.
12 Parnham M, Sies H. Ebselen: prospective therapy for cerebral ischemia. Expert Opin Investig Drugs 2000; 9: 607-19.
13 Yamaguchi T, Sano K, Takakura K. et al for the Ebselen study group. Ebselen in acute ischemic stroke. A placebo-controlled, double-blind clinical trial. Stroke 1998; 29: 12-7.
14 Ogawa A, Yoshimoto T, Kikuchi H. et al for the Ebselen study group. Ebselen in acute middle cerebral artery occlusion: a placebo-controlled, double-blind clinical trial. Cerebrovasc Dis 1999; 9: 112-8.
15 Dimmeler S, Brüne B, Ullrich V. Ebselen prevents inositol (1,4,5)-triphosphate binding to its receptor. Biochem Pharmacol 1991; 42: 1151-3.
16 Brüne B, Diewald B, Ullrich V. Ebselen affects calcium homeostasis in human platelets. Biochem Pharmacol 1991; 41: 1805-1.
17 Baez S. An open cremaster muscle preparation for the study of blood vessels by in vivo microscopy. Microvasc Res 1973; 5: 384-94.
18 Roesken F, Ruecker M, Vollmar B. et al A new model for quantitative in vivo microscopic analysis of thrombus formation and vascular recanalisation: the ear of the hairless (hr/hr) mouse. Thromb Haemost 1997; 78: 1408-4.
19 Vollmar B, Schmitz R, Kunz D. et al Lack of in vivo function of CD31 in vascular thrombosis. Thromb Haemost 2001; 85: 160-4.
20 Denis C, Methia N, Frenette PS. et al A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci USA 1998; 95: 9524-9.
21 Baker M, Wayland H. On-line volume flow rate and velocity profile measurements for blood in microvessels. Microvasc Res 1974; 7: 131-43.
22 Miller FN, Sims DE, Schuschke DA. et al Differentiation of light-dye effects in the micro-circulation. Microvasc Res 1992; 44: 166-84.
23 Lindberg RA, Slaaf DW, Lentsch AB. et al Involvement of nitric oxide and cyclooxygenase products in photoactivation-induced microvascular occlusion. Microvasc Res 1994; 47: 203-21.
24 Saniabadi AR, Umemura K, Matsumoto N. et al Vessel wall injury and arterial thrombosis induced by a photochemical reaction. Thromb Haemost 1995; 73: 868-72.
25 Herrmann KS. Platelet aggregation induced in the hamster cheek pouch by a photochemical process with excited fluorescein isothiocyanate-dextran. Microvasc Res 1983; 26: 238-49.
26 Watson BD, Dietrich WD, Busto R. et al Induction of reproducible brain infarction by photochemically initiated thrombosis. Ann Neurol 1985; 17: 497-504.
27 Haddad el-B, McCluskie K, Birrell MA. et al Differential effects of ebselen on neutrophil recruitment, chemokine, and inflammatory mediator expression in a rat model of lipopolysaccharide-induced pulmonary inflammation. J Immunol 2002; 169: 974-82.
28 Furie B, Furie BC, Flaumenhaft R. A journey with platelet P-selectin: the molecular basis of granule secretion, signalling and cell adhesion. Thromb Haemost 2001; 86: 214-21.
29 Yang J, Furie BC, Furie B. The biology of P-selectin glycoprotein ligand-1: its role as a selectin counterreceptor in leukocyte-endothe-lial and leukocyte-platelet interaction. Thromb Haemost 1999; 81: 1-7.
30 Shebuski RJ, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther 2002; 300: 729-35.
31 Palabrica T, Lobb R, Furie BC. et al Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 1992; 359: 848-51.
32 Celi A, Pellegrini G, Lorenzet R. et al P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci USA 1994; 91: 8767-71.
33 Subramaniam M, Frenette PS, Saffaripour S. et al Defects in hemostasis in P-selectin-deficient mice. Blood 1996; 87: 1238-42.
34 Merten M, Thiagarajan P. P-selectin expression on platelets determines size and stability of platelet aggregates. Circulation 2000; 102: 1931-6.
35 Del Principe DD, Menichelli A, De Matteis W. et al Hydrogen peroxide is an intermediate in the platelet activation cascade triggered by collagen, but not by thrombin. Thromb Res 1991; 62: 365-75.
36 Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 2001; 88: 756-62.
37 Walker TR, Watson SP. Synergy between Ca2+ and protein kinase C is the major factor in determining the level of secretion from human platelets. Biochem J 1993; 289: 277-82.
38 Furie B, Furie BC. Leukocyte crosstalk at the vascular wall. Thromb Haemost 1997; 78: 306-9.
39 Sato M, Ohshima N. Effect of wall shear rate on thrombogenesis in microvessels of the rat mesentery. Circ Res 1990; 66: 941-9.
40 Broeders MA, Tangelder GJ, Slaaf DW. et al Endogenous nitric oxide and prostaglan-dins synergistically counteract thromboembolism in arterioles but not in venules. Arterioscler Thromb Vasc Biol 2001; 21: 163-9.
41 Hashimoto I, Nakanishi H, Shono Y. et al The effects of desferrioxamine on thrombus formation in injured microvessels of the rabbit ear. J Med Invest 1999; 46: 200-4.